Sun.Sep 15, 2024

article thumbnail

STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study 

STAT

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive bladder tumors are treated.  The regimen using Imfinzi, the company’s anti-PD-L1 checkpoint inhibitor, cut the risk of death by 25% compared to treating patients before surgery with chemotherapy alone, researchers reported Sunday.

article thumbnail

Ten-year survival data show long-term benefit of immunotherapy in melanoma

BioPharma Dive

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

122
122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending

STAT

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease. In a study of more than 3,000 samples, the company reported that its test detected 88.3% of cancers and correctly returned a negative result 90.1% of the time, test features known as sensitivity and specificity, respectively.

266
266
article thumbnail

ESMO: Enhertu shows its worth in brain metastases

pharmaphorum

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.

Labelling 108
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

News from ESMO: An AstraZeneca win in bladder cancer, and more

STAT

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions  here. AZ hits in bladder cancer, as regulatory issue looms The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery — cut the risk of death by

226
226
article thumbnail

Top 5 Drugs That Cause Insomnia

Med Ed 101

Many drugs cause insomnia. What is most frustrating to me in my practice is when we start medications for a “new condition” prior to ruling out medication adverse effects. Here is the list of my top 5 drugs that cause insomnia (an important adverse effect that could show up on your board exam). Corticosteroids. They […] The post Top 5 Drugs That Cause Insomnia appeared first on Med Ed 101.

105
105

More Trending

article thumbnail

US FDA approves Eli Lilly’s drug for eczema

Express Pharma

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, which is an injectable medicine and branded Ebglyss, will be available in the next few weeks, the company said. Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches.

80
article thumbnail

ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases

Pharmaceutical Technology

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.

93
article thumbnail

The Greatest Trick the Devil Ever Pulled was Convincing the World He Didn’t Exist: Senate Judiciary Set to Mark-Up Patent Reform Bills that Could Significantly Affect Hatch-Waxman and the BPCIA

FDA Law Blog: Biosimilars

By Kurt R. Karst — “Inter Partes Review” and “Section 101” are not terms you typically run into on this all-things-FDA blog, but we have talked about such patent-related issues before ( here and here ), and they are important legal (patent) principles, particularly in the context of drug and biological products (and the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (“BPCIA”)).

article thumbnail

Is Retail Pharmacy Right For You?

The Happy PharmD

Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.

article thumbnail

Grow Big, Pay Smart: How To Unlock Efficiency In Payroll Management

Speaker: Joe Sharpe and James Carlson

Running a small business is no small feat. Payroll management, in particular, can be one of the most time-consuming and complex parts of that equation. Yet, businesses that crack the code on streamlining these processes often discover not just savings, but new avenues for growth. Our expert speakers will share actionable insights and real-world examples of how businesses have reduced overhead and improved payroll efficiency.

article thumbnail

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Pharmaceutical Technology

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.

52
article thumbnail

Is Retail Pharmacy Right For You?

The Happy PharmD

Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.

article thumbnail

Securing the Supply Chain for Small-Molecule APIs and Excipients & Minimal API

PharmaTech

Webinar Date/Time: Fri, Sep 27, 2024 11:00 AM EDT

52
article thumbnail

State of Well-Being 2023-2024

The Happy PharmD

Wondering how our healthcare professionals, especially pharmacists, are faring lately? Well, now’s the perfect time to dive into a discussion with me about the latest insights from the 2023 report by the Well-Being Index. Whether you’re new here or a regular viewer, a warm welcome awaits you! And if you’re eager to stay updated with insightful content, don’t forget to hit that subscribe button and notification bell.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC

Pharmacy Times

Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.

article thumbnail

Episode 957: Not every professional critical care society is high on ketamine for analgosedation

Pharmacy Joe

In this episode, I’ll discuss a recent practice guideline on ketamine use for analgosedation in critically ill patients. Episode 957: Not every professional critical care society is high on ketamine for analgosedation Subscribe on iTunes , Android , or Stitcher The 2018 PADIS Guidelines published by the Society of Critical Care Medicine gave a positive recommendation for the use of ketamine saying: We suggest using low-dose ketamine (0.5 mg/kg IVP x 1 followed by 1-2 μg/kg/min infusion) as an ad

article thumbnail

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

Pharmacy Times

Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.

29